Denali Therapeutics Inc. (DNLI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 30.53 |
| Open | 30.53 |
| Bid | 30.70 x 1100 |
| Ask | 33.85 x 800 |
| Day's Range | 30.53 - 31.97 |
| 52 Week Range | 20.24 - 39.43 |
| Volume | |
| Avg. Volume | 661,952 |
| Market Cap | 4.274B |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.21 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DNLI
Related Research
- Denali Therapeutics Inc.Daily – Vickers Top Buyers & Sellers for 07/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
- GlobeNewswire
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiationDevelopment of RIPK1 inhibitor program continues in a broad range of central nervous system and peripheral inflammatory conditions SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing
- GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’s diseaseFurther validation and expansion of Transport Vehicle (TV) technology, including multiple interim clinical data readouts, submission of IND for additional ETV program, and selection of five Oligonucleotide TV (OTV) targetsContinued invention and scientific insights in neurodegeneration biology fuel broad early-stage pipeline of therapeutic candidates SOUTH SAN FRANCISCO, Ca
- Simply Wall St.
With 63% ownership, Denali Therapeutics Inc. (NASDAQ:DNLI) boasts of strong institutional backing
Every investor in Denali Therapeutics Inc. ( NASDAQ:DNLI ) should be aware of the most powerful shareholder groups. We...
